Rhythm Pharmaceuticals receives FDA approval for expanded IMCIVREE indication

March 19, 2026 6:30 PM

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) announced the U.S. Food and Drug Administration has approved an expanded indication for IMCIVREE (setmelanotide) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found